Icon Press Center

Press Center

Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.

Read Full Article

Patient Voice 2026

Throughout Septembre Rouge 2026, Priothera SAS invited Carolina, an AML patient advocate, to share her story in a four-part video series.

From the shock of diagnosis and the journey through stem cell transplantation to life after transplant and her hopes for the future, Carolina speaks openly about what it means to live with AML — and about the challenges that remain after transplantation.

Her story gives a voice to many patients who are waiting for more effective maintenance treatments to help prevent relapse and improve long-term outcomes — and echoes Priothera’s commitment to addressing this unmet need.

Watch the four videos:

1. The day everything changed

2. The donor who gave me a second chance

3. Life after transplant

4. My wish for innovative maintenance treatment

Priothera receives a European Union grant of nearly € 685.000 for the development of its innovative treatment for hematologic cancers

Priothera receives a European Union grant of nearly € 685.000 for the development of its innovative treatment for hematologic cancers

July 2025
As part of the 2021–2027 FEDER-FTJ-FSE+ Program for the Grand Est and Vosges Massif region. St-Louis, France – July 11, 2025 – Priothera, a late-stage biopharmaceutical company specializing in the development of innovative oncology treatments, today announces that it has secured funding of €684,939 from the Fondss pour une Transition Juste (FTJ) – Just Transition Fund – under the 2021–2027 FEDER-FTJ-FSE+ Program for the Grand Est and Vosges Massif region, managed by the Grand Est Regional Council.
Read Full Article
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program

June 2025
Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy. Saint-Louis, France and Dublin, Ireland – 24 June 2025– Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced that it has been awarded nearly €1.7 million in non-dilutive funding through the i-Nov innovation competition.
Read Full Article
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen

Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen

June 2025
Saint-Louis, France and Dublin, Ireland – 3rd June 2025 – Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced the appointment of Dr. Hans Menssen, MD, PhD, BBA, to its Board of Directors.
Read Full Article
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)

Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)

May 2025
Saint-Louis, France and Dublin, Ireland – 6th May 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced the appointment of Jens Hasskarl, MD, PhD, as Chief Medical Officer (CMO).
Read Full Article
Innover pour mieux soigner – Les cancers du sang avec Priothera

Innover pour mieux soigner – Les cancers du sang avec Priothera

April 2025
Florent Gros, Cofondateur et Président de Priothera, nous dévoile les ambitions de son entreprise spécialisée dans le traitement des hémopathies malignes, notamment la leucémie myéloïde aiguë (LMA). Entre innovation thérapeutique et défis d’une biotech en pleine croissance, il nous partage sa vision pour transformer les traitements et améliorer la survie des patients atteints de cancers du sang.
Read Full Article
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting

Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting

December 2024
Mocravimod is being investigated in a global MO-TRANS Phase III study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation...
Read Full Article
Load More...
No results found.